TP53 and Miyoshi myopathy: Although MM with TP53 lesions appears to be per se responsive to therapies with novel agents15–17, the acquisition of additional oncogenic driver events, often in combination with outgrowth of a TP53 double-hit clone, appears to underlie the fast progress into intractable and fatal disease18.